SF1670
目录号 : GC10019
SF1670是一种有效的特异性PTEN（第10号染色体上缺失的磷酸酶和张力蛋白同源物）抑制剂。
Cas No.:345630-40-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SF1670 is a potent and specific PTEN (phosphatase and tensin homolog deleted on chromosome 10) inhibitor[1]. SF1670 protects cells from oxygen-glucose deprivation-induced cell death[2]. SF1670 helps maintain the pluripotency of mouse embryonic stem cells (ESCs)[3].
In vitro, treatment of nucleus pulposus (NP) cells with SF1670 (0-5µM) for 3h significantly increased cell viability, inhibited PTEN expression, and activated Akt activity[4]. Pretreatment of neutrophils with SF1670 (125-500nM) for 30min dose-dependently enhanced fMLP-induced neutrophil polarization[5]. Treatment of MCF-7 cells with SF1670 (200nM) for 48h significantly inhibited curcumin-induced cell apoptosis and significantly upregulated p-AKT protein expression[6].
In vivo, SF1670 (3mg/kg) was intraperitoneally injected into mice with cerebral ischemia-reperfusion (I/R) injury, which attenuated the increase in thiobarbituric acid reactive substances (TBARS) induced by I/R and reversed the decrease in GSH levels and SOD activity[7].
References:
[1] Li F Q, Chen W B, Luo Z W, et al. Bone marrow mesenchymal stem cell-derived exosomal microRNAs target PI3K/Akt signaling pathway to promote the activation of fibroblasts[J]. World Journal of Stem Cells, 2023, 15(4): 248.
[2] Farajdokht F, Mohaddes G, Karimi-Sales E, et al. Inhibition of PTEN protects PC12 cells against oxygen-glucose deprivation induced cell death through mitoprotection[J]. Brain research, 2018, 1692: 100-109.
[3] Wang W, Lu G, Su X, et al. Pten-mediated Gsk3β modulates the naïve pluripotency maintenance in embryonic stem cells[J]. Cell Death & Disease, 2020, 11(2): 107.
[4] Fu H Y, Shen L, Gao X S, et al. SF1670 inhibits apoptosis and inflammation via the PTEN/Akt pathway and thus protects intervertebral disc degeneration[J]. European Review for Medical & Pharmacological Sciences, 2020, 24(17).
[5] Li Y, Prasad A, Jia Y, et al. Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670 augments the efficacy of granulocyte transfusion in a clinically relevant mouse model[J]. Blood, The Journal of the American Society of Hematology, 2011, 117(24): 6702-6713.
[6] Li M Z, Wang C R, Lin C L. Curcumin promotes apoptosis of breast cancer cells by down-regulating DJ-1-PTEN/PI3K/AKT signaling pathways[J]. Int. J. Clin. Exp. Med, 2019, 12: 8992-8998.
[7] Grewal A K, Singh N, Singh T G. Neuroprotective effect of pharmacological postconditioning on cerebral ischaemia–reperfusion-induced injury in mice[J]. Journal of Pharmacy and Pharmacology, 2019, 71(6): 956-970.
SF1670是一种有效的特异性PTEN（第10号染色体上缺失的磷酸酶和张力蛋白同源物）抑制剂[1]。SF1670能够保护细胞免受氧-葡萄糖剥夺诱导的细胞死亡[2]。SF1670有助于维持小鼠胚胎干细胞（ESC）的多能性[3]。
在体外，SF1670（0-5µM）处理髓核（NP）细胞3h，显著提高了细胞活力，抑制了PTEN的表达，激活了Akt活性[4]。SF1670（125-500nM）预处理中性粒细胞30min，剂量依赖性地增强了fMLP诱导的中性粒细胞极化[5]。SF1670（200nM）处理MCF-7细胞48h，显著抑制了姜黄素引起的细胞凋亡，显著上调了p-AKT蛋白表达[6]。
在体内，SF1670（3mg/kg）通过腹腔注射治疗脑缺血再灌注（I/R）损伤小鼠，减弱了I/R引起的硫代巴比妥酸反应物质（TBARS）的增加，逆转了GSH水平和SOD活性的下降[7]。
| Cell experiment [1]: | |
Cell lines | Nucleus pulposus (NP) cells |
Preparation Method | NP cells were treated with 0, 0.5, 1, 2, and 5μM SF1670 for 3h, and then cell viability was measured using the CCK-8 assay. |
Reaction Conditions | 0, 0.5, 1, 2, and 5µM; 3h |
Applications | SF1670 treatment can improve the viability of NP cells, and the cell viability reached the highest level when treated with 2μM concentration. |
| Animal experiment [2]: | |
Animal models | Swiss albino male mice |
Preparation Method | Six male mice in each group were randomly selected and divided into nine groups. All the animals were subjected to behavioral tests and biochemical estimations during the study. Group I was a sham surgery group, and group II was I/R control group. For the reperfusion intervention (i.e. pPoCo), pharmacological agents CGS21680 (0.5mg/kg; i.p.) (in group V, VI, IX) and SF1670 (3mg/kg; i.p.) (in group VII, VIII, IX) were administered 5min before reper fusion of 24h so that the drug would be in circulation at the time of onset of reperfusion. |
Dosage form | 3mg/kg; i. p. |
Applications | SF1670 treatment attenuated the I/R-induced increase in thiobarbituric acid reactive substances (TBARS), and reversed the decrease in GSH levels and SOD activity. |
References: | |
| Cas No. | 345630-40-2 | SDF | |
| 化学名 | N-(9,10-dioxo-9,10-dihydrophenanthren-2-yl)pivalamide | ||
| Canonical SMILES | CC(C)(C(NC(C=C1C2=O)=CC=C1C3=C(C2=O)C=CC=C3)=O)C | ||
| 分子式 | C19H17NO3 | 分子量 | 307.34 |
| 溶解度 | ≥ 15.37mg/mL in DMSO | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2537 mL | 16.2686 mL | 32.5373 mL |
| 5 mM | 0.6507 mL | 3.2537 mL | 6.5075 mL |
| 10 mM | 0.3254 mL | 1.6269 mL | 3.2537 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet